Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative
Although most individuals recover from acute SARS-CoV-2 infection, a significant number continue to suffer from Post-Acute Sequelae of SARS-CoV-2 (PASC), including the unexplained symptoms that are frequently referred to as long COVID, which could last for weeks, months, or even years after the acut...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129459/full |
| _version_ | 1811157722336329728 |
|---|---|
| author | Hector Bonilla Michael J. Peluso Kathleen Rodgers Judith A. Aberg Thomas F. Patterson Robert Tamburro Lawrence Baizer Jason D. Goldman Jason D. Goldman Nadine Rouphael Amelia Deitchman Jeffrey Fine Paul Fontelo Arthur Y. Kim Gwendolyn Shaw Jeran Stratford Patricia Ceger Maged M. Costantine Liza Fisher Lisa O’Brien Christine Maughan John G. Quigley Vilma Gabbay Sindhu Mohandas David Williams Grace A. McComsey |
| author_facet | Hector Bonilla Michael J. Peluso Kathleen Rodgers Judith A. Aberg Thomas F. Patterson Robert Tamburro Lawrence Baizer Jason D. Goldman Jason D. Goldman Nadine Rouphael Amelia Deitchman Jeffrey Fine Paul Fontelo Arthur Y. Kim Gwendolyn Shaw Jeran Stratford Patricia Ceger Maged M. Costantine Liza Fisher Lisa O’Brien Christine Maughan John G. Quigley Vilma Gabbay Sindhu Mohandas David Williams Grace A. McComsey |
| author_sort | Hector Bonilla |
| collection | DOAJ |
| description | Although most individuals recover from acute SARS-CoV-2 infection, a significant number continue to suffer from Post-Acute Sequelae of SARS-CoV-2 (PASC), including the unexplained symptoms that are frequently referred to as long COVID, which could last for weeks, months, or even years after the acute phase of illness. The National Institutes of Health is currently funding large multi-center research programs as part of its Researching COVID to Enhance Recover (RECOVER) initiative to understand why some individuals do not recover fully from COVID-19. Several ongoing pathobiology studies have provided clues to potential mechanisms contributing to this condition. These include persistence of SARS-CoV-2 antigen and/or genetic material, immune dysregulation, reactivation of other latent viral infections, microvascular dysfunction, and gut dysbiosis, among others. Although our understanding of the causes of long COVID remains incomplete, these early pathophysiologic studies suggest biological pathways that could be targeted in therapeutic trials that aim to ameliorate symptoms. Repurposed medicines and novel therapeutics deserve formal testing in clinical trial settings prior to adoption. While we endorse clinical trials, especially those that prioritize inclusion of the diverse populations most affected by COVID-19 and long COVID, we discourage off-label experimentation in uncontrolled and/or unsupervised settings. Here, we review ongoing, planned, and potential future therapeutic interventions for long COVID based on the current understanding of the pathobiological processes underlying this condition. We focus on clinical, pharmacological, and feasibility data, with the goal of informing future interventional research studies. |
| first_indexed | 2024-04-10T05:12:08Z |
| format | Article |
| id | doaj.art-eb98a60c1b42411c806eac87aaa2342b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T05:12:08Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-eb98a60c1b42411c806eac87aaa2342b2023-03-09T07:20:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11294591129459Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiativeHector Bonilla0Michael J. Peluso1Kathleen Rodgers2Judith A. Aberg3Thomas F. Patterson4Robert Tamburro5Lawrence Baizer6Jason D. Goldman7Jason D. Goldman8Nadine Rouphael9Amelia Deitchman10Jeffrey Fine11Paul Fontelo12Arthur Y. Kim13Gwendolyn Shaw14Jeran Stratford15Patricia Ceger16Maged M. Costantine17Liza Fisher18Lisa O’Brien19Christine Maughan20John G. Quigley21Vilma Gabbay22Sindhu Mohandas23David Williams24Grace A. McComsey25Department of Medicine and Infectious Diseases, Stanford University, Palo Alto, CA, United StatesDepartment of Medicine and Infectious Diseases, University of California, San Francisco, San Francisco, CA, United StatesCenter for Innovations in Brain Science, University of Arizona, Tucson, AZ, United StatesDepartment of Medicine, Infectious Diseases, Icahn School of Medicine at Mount Sinai, Chief, Division of Infectious Disease, New York, NY, United StatesDepartment of Medicine, Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United StatesDivision of Intramural Research, National Institute of Health, Bethesda, MD, United StatesNational Heart Lung and Blood Institute, Division of Lung Diseases, National Institutes of Health, Bethesda, MD, United StatesDepartment of Medicine, Organ Transplant and Liver Center, Swedish Medical Center, Seattle, WA, United StatesDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States0Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States1Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, United States2Department of Rehabilitation Medicine at New York University (NYU) Grossman School of Medicine, Physical Medicine and Rehabilitation Service, New York University (NYU), New York University Medical Center, New York, NY, United States3Applied Clinical Informatics Branch, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States4Department of Medicine at Harvard Medical School, Division of Infectious Disease, Boston, MA, United States5Research Triangle Institute (RTI), International, Durham, NC, United States5Research Triangle Institute (RTI), International, Durham, NC, United States5Research Triangle Institute (RTI), International, Durham, NC, United States6Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States7Long COVID Families, Houston, TX, United States8Utah Covid-19 Long Haulers, Salt Lake City, UT, United States8Utah Covid-19 Long Haulers, Salt Lake City, UT, United States9Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States0Department of Medicine, Albert Einstein College of Medicine, New York, NY, United States1Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States2Department of Medicine, University of Michigan, Ann Arbor, MI, United States3Department of Pediatrics and Medicine, Case Western Reserve University, Cleveland, OH, United StatesAlthough most individuals recover from acute SARS-CoV-2 infection, a significant number continue to suffer from Post-Acute Sequelae of SARS-CoV-2 (PASC), including the unexplained symptoms that are frequently referred to as long COVID, which could last for weeks, months, or even years after the acute phase of illness. The National Institutes of Health is currently funding large multi-center research programs as part of its Researching COVID to Enhance Recover (RECOVER) initiative to understand why some individuals do not recover fully from COVID-19. Several ongoing pathobiology studies have provided clues to potential mechanisms contributing to this condition. These include persistence of SARS-CoV-2 antigen and/or genetic material, immune dysregulation, reactivation of other latent viral infections, microvascular dysfunction, and gut dysbiosis, among others. Although our understanding of the causes of long COVID remains incomplete, these early pathophysiologic studies suggest biological pathways that could be targeted in therapeutic trials that aim to ameliorate symptoms. Repurposed medicines and novel therapeutics deserve formal testing in clinical trial settings prior to adoption. While we endorse clinical trials, especially those that prioritize inclusion of the diverse populations most affected by COVID-19 and long COVID, we discourage off-label experimentation in uncontrolled and/or unsupervised settings. Here, we review ongoing, planned, and potential future therapeutic interventions for long COVID based on the current understanding of the pathobiological processes underlying this condition. We focus on clinical, pharmacological, and feasibility data, with the goal of informing future interventional research studies.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129459/fullpost-acute sequela of SARS-CoV-2 (PASC)long COVIDSARS- CoV-2long haulerstreatmentclinical trials |
| spellingShingle | Hector Bonilla Michael J. Peluso Kathleen Rodgers Judith A. Aberg Thomas F. Patterson Robert Tamburro Lawrence Baizer Jason D. Goldman Jason D. Goldman Nadine Rouphael Amelia Deitchman Jeffrey Fine Paul Fontelo Arthur Y. Kim Gwendolyn Shaw Jeran Stratford Patricia Ceger Maged M. Costantine Liza Fisher Lisa O’Brien Christine Maughan John G. Quigley Vilma Gabbay Sindhu Mohandas David Williams Grace A. McComsey Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative Frontiers in Immunology post-acute sequela of SARS-CoV-2 (PASC) long COVID SARS- CoV-2 long haulers treatment clinical trials |
| title | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative |
| title_full | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative |
| title_fullStr | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative |
| title_full_unstemmed | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative |
| title_short | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative |
| title_sort | therapeutic trials for long covid 19 a call to action from the interventions taskforce of the recover initiative |
| topic | post-acute sequela of SARS-CoV-2 (PASC) long COVID SARS- CoV-2 long haulers treatment clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129459/full |
| work_keys_str_mv | AT hectorbonilla therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT michaeljpeluso therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT kathleenrodgers therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT judithaaberg therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT thomasfpatterson therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT roberttamburro therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT lawrencebaizer therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT jasondgoldman therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT jasondgoldman therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT nadinerouphael therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT ameliadeitchman therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT jeffreyfine therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT paulfontelo therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT arthurykim therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT gwendolynshaw therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT jeranstratford therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT patriciaceger therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT magedmcostantine therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT lizafisher therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT lisaobrien therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT christinemaughan therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT johngquigley therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT vilmagabbay therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT sindhumohandas therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT davidwilliams therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative AT graceamccomsey therapeutictrialsforlongcovid19acalltoactionfromtheinterventionstaskforceoftherecoverinitiative |